Barry Bertolet, MD
Cardiovascular Disease · Tupelo, MSNPI 1295845444
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $303,454 of the $469,253 with a category attached, or 64.7%. 60 manufacturers reported payments, led by Medtronic at 36.9% of the total. Among cardiovascular disease clinicians in MS with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,104 payments — averaging $425.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$173K
- AstraZeneca$87K
- Shockwave Medical, Inc$47K
- Amgen$40K
- Amarin Pharma, Inc.$34K
- Esperion Therapeutics, Inc.$20K
- plus $68K from 54 others
Across 684 payments — averaging $8695.27 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Medtronic$2.2M
- Novartis$1.2M
- Amgen$492K
- Shockwave Medical, Inc$447K
- Janssen Research & Development, LLC$414K
- E.r. Squibb & Sons, L.L.C.$262K
- plus $913K from 14 others
What the payments were for
- Consulting fees$99,23121%
- Speaking & faculty fees$303,45465%
- Travel & lodging$35,4278%
- Food & beverage$30,5827%
- Education$5590%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FARXIGA$85,069
- SYMPLICITY G3$67,462
- Repatha$38,645
- Vascepa$33,654
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$31,692
- NEXLIZET$19,736
- NEXLETOL$19,736
- Vascular Lithotripsy$14,831
- PRALUENT$11,621
- Ozempic$9,081
- LEQVIO$8,641
- IN.PACT Admiral$5,706
- INTERVENTIONAL ANGIOGRAPHY SYSTEM$4,000
- DyeVert$3,547
- Cardiva VASCADE MVP VVCS 6-12F$3,500
- GENERAL NON-EQUIPMENT$2,500
- Aggrastat (tirofiban HCl)$1,925
- Vascular Closure Device$1,300
- Torus Stent Graft System$687
- ENDOCROSS Device$687
How this compares
$469,253 in reported general payments places this provider in the 95th percentile of 144 cardiovascular disease providers in Mississippi.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CamzyosMavacamten | 146 | $1,189,838 |
| EliquisApixaban | 482 | $400,079 |
| Repatha SureclickEvolocumab | 227 | $207,402 |
| FarxigaDapagliflozin Propanediol | 180 | $160,212 |
| XareltoRivaroxaban | 158 | $104,781 |
| EntrestoSacubitril/Valsartan | 95 | $89,580 |
| JardianceEmpagliflozin | 96 | $87,303 |
| Praluent PenAlirocumab | 80 | $62,862 |
| BrilintaTicagrelor | 62 | $36,932 |
| VascepaIcosapent Ethyl | 27 | $19,106 |
| Ezetimibe | 874 | $15,979 |
| Propafenone Hcl | 397 | $13,657 |
| Ranolazine ErRanolazine | 159 | $12,942 |
| Rosuvastatin Calcium | 1,232 | $12,308 |
| Metoprolol Succinate | 874 | $11,369 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| E.r. Squibb & Sons, L.L.C.Camzyos | $3,234 | $1,189,838146 claims |
| PfizerEliquis | $428 | $400,079482 claims |
| AstraZenecaFarxiga, Brilinta | $87,103 | $197,143242 claims |
| Johnson & JohnsonXarelto | $265 | $104,781158 claims |
| NovartisEntresto | $9,123 | $89,58095 claims |
| Boehringer IngelheimJardiance | $943 | $87,30396 claims |
| MerckJanuvia | $691 | $9,00811 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 144 cardiovascular disease providers in Mississippi.
Other cardiovascular disease in Tupelo
- Benjamin BlossomTupelo$7K
- Michael BolerTupelo$6K
- Dharmesh PatelSouthaven$1.5M
- Donny StokesJackson$207K
- Mahmoud ZayedPascagoula$103K
- James BenslerJackson$64K
- Michael HallJackson$54K
- Hugo QuintanaPascagoula$48K
- Ediz TasanPascagoula$42K
- Lawrence LeaderHattiesburg$40K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.